{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:18:50Z","timestamp":1792192730590,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[1999,10]]},"DOI":"10.1053\/hj.1999.v138.a100459","type":"journal-article","created":{"date-parts":[[2004,7,28]],"date-time":"2004-07-28T10:40:39Z","timestamp":1091011239000},"page":"S263-S275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"S","title":["Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors"],"prefix":"10.1053","volume":"138","author":[{"given":"Neal S.","family":"Kleiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/hj.1999.v138.a100459_BIB1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100459_BIB2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0002-9149(96)00749-7","article-title":"Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb\/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization","volume":"79","author":"Lincoff","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB3","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100459_BIB4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.a100459_BIB5","first-page":"1219","article-title":"Bleeding time: a guide to its diagnostic and clinical utility","volume":"113","author":"Burns","year":"1989","journal-title":"Arch Pathol Lab Med"},{"key":"10.1053\/hj.1999.v138.a100459_BIB6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/0002-9149(93)90979-M","article-title":"Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb\/IIIa platelet antibody","volume":"72","author":"Bernardi","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1113\/jphysiol.1963.sp007185","article-title":"The aggregation of blood platelets","volume":"168","author":"Born","year":"1963","journal-title":"J Physiol (Lond)"},{"key":"10.1053\/hj.1999.v138.a100459_BIB8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0049-3848(90)90242-5","article-title":"Extracellular-free Ca++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma","volume":"58","author":"Bell","year":"1990","journal-title":"Thromb Res"},{"key":"10.1053\/hj.1999.v138.a100459_BIB9","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1016\/S0021-9258(17)44449-8","article-title":"Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes","volume":"258","author":"Fujimura","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1053\/hj.1999.v138.a100459_BIB10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood.V71.4.831.831","article-title":"The platelet membrane glycoprotein IIb-IIIa complex","volume":"71","author":"Phillips","year":"1988","journal-title":"Blood"},{"key":"10.1053\/hj.1999.v138.a100459_BIB11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0021-9258(19)86278-6","article-title":"Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation","volume":"255","author":"Marguerie","year":"1980","journal-title":"J Biol Chem"},{"key":"10.1053\/hj.1999.v138.a100459_BIB12","doi-asserted-by":"crossref","first-page":"21745","DOI":"10.1074\/jbc.271.36.21745","article-title":"An allosteric Ca2+ binding site on the \u03b23-integrins that regulates the dissociation rate for RGD ligands","volume":"271","author":"Hu","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1053\/hj.1999.v138.a100459_BIB13","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1074\/jbc.270.17.9917","article-title":"Ca2+ suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin \u03b1v\u03b23","volume":"270","author":"Hu","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1053\/hj.1999.v138.a100459_BIB14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0092-8674(94)90551-7","article-title":"Ligand and cation binding are dual functions of a discrete segment of the integrin \u03b23 subunit: cation displacement is involved in ligand binding","volume":"79","author":"D\u2019Souza","year":"1994","journal-title":"Cell"},{"key":"10.1053\/hj.1999.v138.a100459_BIB15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1642390","article-title":"Antithrombotic effects and bleeding time prolongation with synthetic platelet GP IIb\/IIIa inhibitors in animal models of platelet-mediated thrombosis","volume":"71","author":"Collen","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1053\/hj.1999.v138.a100459_BIB16","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1161\/01.CIR.96.5.1488","article-title":"Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate","volume":"96","author":"Phillips","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/01.ATV.18.6.954","article-title":"In vivo efficacy of SM-20302, a GP IIb\/IIIa receptor antagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood","volume":"18","author":"Rebello","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB18","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/01.CIR.98.16.1616","article-title":"Differential effects of glycoprotein IIb\/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: implications for assay methodology and comparison of different antagonists","volume":"98","author":"Storey","year":"1998","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB19","first-page":"357","article-title":"Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition","volume":"34","author":"Kuzniar","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1053\/hj.1999.v138.a100459_BIB20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1172\/JCI111705","article-title":"Functionally thrombasthenic state in normal platelets following the administration of ticlopidine","volume":"75","author":"DiMinno","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1053\/hj.1999.v138.a100459_BIB21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0735-1097(95)00500-5","article-title":"Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb\/IIIa blockade in high risk patients undergoing coronary angioplasty","volume":"27","author":"Kereiakes","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.94.5.899","article-title":"Platelet membrane receptor glycoprotein IIb\/IIIa antagonism in unstable angina: the Canadian lamifiban study","volume":"94","author":"Theroux","year":"1996","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB23","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1161\/01.CIR.90.4.1757","article-title":"Pharmacodynamics of chimeric glycoprotein IIb\/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty","volume":"90","author":"Tcheng","year":"1994","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB24","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0002-9149(99)80345-2","article-title":"Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb\/IIIa inhibitor during percutaneous coronary intervention","volume":"76","author":"Harrington","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB25","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"key":"10.1053\/hj.1999.v138.a100459_BIB26","first-page":"270","article-title":"Molecular mechanisms of thrombin signaling","volume":"31","author":"Coughlin","year":"1994","journal-title":"Semin Hematol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB27","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI116344","article-title":"The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation","volume":"91","author":"Bahou","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1053\/hj.1999.v138.a100459_BIB28","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/0735-1097(95)00391-6","article-title":"Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb\/IIIa receptors","volume":"26","author":"Kleiman","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB29","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood.V66.6.1456.1456","article-title":"Inhibition of dog platelet function by in vivo infusion of F(ab\u2019)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb\/IIIa receptor","volume":"66","author":"Coller","year":"1985","journal-title":"Blood"},{"key":"10.1053\/hj.1999.v138.a100459_BIB30","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.CIR.77.3.670","article-title":"Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb\/IIIa antibody in a canine preparation","volume":"77","author":"Gold","year":"1988","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB31","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1161\/01.CIR.96.11.3860","article-title":"Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb\/IIIa therapy","volume":"96","author":"Mascelli","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-1000376","article-title":"Anti-GP IIb\/IIIa antibodies: powerful tools to investigate function and regulation of an integrin","volume":"21","author":"Bachelot","year":"1995","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/hj.1999.v138.a100459_BIB33","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood.V88.10.3824.bloodjournal88103824","article-title":"Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor","volume":"88","author":"Mondoro","year":"1996","journal-title":"Blood"},{"key":"10.1053\/hj.1999.v138.a100459_BIB34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.CIR.97.1.5","article-title":"Monitoring platelet GP IIb\/IIIa antagonist therapy","volume":"97","author":"Coller","year":"1998","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1213\/00000539-198509000-00008","article-title":"Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation","volume":"64","author":"Kang","year":"1985","journal-title":"Anesth Analg"},{"key":"10.1053\/hj.1999.v138.a100459_BIB36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1213\/00000539-199701000-00006","article-title":"A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients","volume":"84","author":"Greilich","year":"1997","journal-title":"Anesth Analg"},{"key":"10.1053\/hj.1999.v138.a100459_BIB37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1182\/blood.V81.5.1263.1263","article-title":"Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets","volume":"81","author":"Alevriadou","year":"1993","journal-title":"Blood"},{"key":"10.1053\/hj.1999.v138.a100459_BIB38","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood.V85.7.1826.bloodjournal8571826","article-title":"Platelet adhesion and aggregation on human type VI collagen surfaces under physiological flow conditions","volume":"85","author":"Ross","year":"1995","journal-title":"Blood"},{"key":"10.1053\/hj.1999.v138.a100459_BIB39","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.81.3.1106","article-title":"Aurintricarboxylic acid in a canine model of coronary artery thrombosis","volume":"81","author":"Strony","year":"1990","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB40","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1161\/01.CIR.91.5.1427","article-title":"Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb\/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty","volume":"91","author":"Konstantopoulos","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB41","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.CIR.90.2.988","article-title":"Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: relative contribution of fibrin(ogen) and platelets","volume":"90","author":"Mailhac","year":"1994","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB42","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/01.CIR.91.5.1354","article-title":"Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa","volume":"91","author":"Turner","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0160-5402(80)90024-8","article-title":"The electronic aggregometer: a novel device for assessing platelet behavior in blood","volume":"3","author":"Cardinal","year":"1980","journal-title":"J Pharmacol Methods"},{"key":"10.1053\/hj.1999.v138.a100459_BIB44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ajcp\/85.1.50","article-title":"Critical evaluation of platelet aggregation in whole human blood","volume":"85","author":"Riess","year":"1986","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB45","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/ajcp\/92.5.676","article-title":"Whole blood aggregometry: influence of sample collection and delay in study performance on test results","volume":"92","author":"Sweeney","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ajcp\/91.2.159","article-title":"Ability of whole blood aggregometer to detect platelet hyperaggregability","volume":"91","author":"Abbate","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/ajcp\/95.1.82","article-title":"Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders","volume":"95","author":"Balduini","year":"1991","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB48","author":"Jordan","year":"1996"},{"key":"10.1053\/hj.1999.v138.a100459_BIB49","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2165\/00003495-199448040-00007","article-title":"Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease","volume":"48","author":"Faulds","year":"1994","journal-title":"Drugs"},{"key":"10.1053\/hj.1999.v138.a100459_BIB50","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.97.17.1680","article-title":"Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb\/IIIa receptor blockade","volume":"97","author":"Mascelli","year":"1998","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB51","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/01.CIR.89.2.596","article-title":"Randomized trial of a GP IIb\/IIIa platelet receptor blocker in refractory unstable angina","volume":"89","author":"Simoons","year":"1994","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study","volume":"349","author":"CAPTURE Investigators","year":"1997","journal-title":"Lancet"},{"issue":"suppl A","key":"10.1053\/hj.1999.v138.a100459_BIB53","doi-asserted-by":"crossref","first-page":"238A","DOI":"10.1016\/S0735-1097(97)84740-7","article-title":"Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting","volume":"31","author":"Kleiman","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB54","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/01.ATV.13.3.393","article-title":"Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine","volume":"13","author":"Cattaneo","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1053\/hj.1999.v138.a100459_BIB55","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-128-7-199804010-00004","article-title":"Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases","volume":"128","author":"Bennett","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1053\/hj.1999.v138.a100459_BIB56","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0003-4975(97)01299-X","article-title":"Abciximab and excessive bleeding in patients undergoing emergency cardiac operations","volume":"65","author":"Gammie","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/hj.1999.v138.a100459_BIB57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0002-9149(97)00286-5","article-title":"Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab","volume":"80","author":"Juergens","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB58","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1016\/S0021-9258(18)92826-7","article-title":"Barbourin: a GP IIb-IIIa-specific integrin antagonist from the venom of Sistrurus m barbouri","volume":"266","author":"Scarborough","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1053\/hj.1999.v138.a100459_BIB59","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0021-9258(18)54041-2","article-title":"Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms","volume":"268","author":"Scarborough","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1053\/hj.1999.v138.a100459_BIB60","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/S0002-9149(97)00572-9","article-title":"Clinical pharmacology of eptifibatide","volume":"80","author":"Phillips","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100459_BIB61","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II","volume":"349","author":"IMPACT-II Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.a100459_BIB62","first-page":"624","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade with high-dose Integrilin in coronary intervention: results of the PRIDE study","volume":"18","author":"Tcheng","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1053\/hj.1999.v138.a100459_BIB63","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100459_BIB64","first-page":"355","article-title":"Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb\/IIIA receptor","author":"Deckelbaum","year":"1997"},{"key":"10.1053\/hj.1999.v138.a100459_BIB65","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.1994.152","article-title":"Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb\/IIIa receptor antagonist, in healthy men","volume":"56","author":"Barrett","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/hj.1999.v138.a100459_BIB66","first-page":"I","article-title":"A heparin-controlled study of MK-383 in unstable angina","volume":"90","author":"Theroux","year":"1994","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100459_BIB67","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","article-title":"International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina","volume":"97","author":"PARAGON Investigators","year":"1998","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870399004482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870399004482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:03:21Z","timestamp":1757567001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870399004482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["S0002870399004482"],"URL":"https:\/\/doi.org\/10.1053\/hj.1999.v138.a100459","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[1999,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/hj.1999.v138.a100459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}